<?xml version="1.0" encoding="UTF-8"?>
<p>To reduce the inflammatory response, inhibitors of IL-1 and IL-6 and the Janus kinase JAK1/JAK2 inhibitor baricitinib are being studied [
 <xref rid="C177" ref-type="bibr">177</xref>, 
 <xref rid="C178" ref-type="bibr">178</xref>]. Azithromycin may be of potential interest for its immunomodulatory effect [
 <xref rid="C179" ref-type="bibr">179</xref>], although data on its efficacy are lacking and its effect on antimicrobial resistance should be considered. IFNs are being tested because of their stimulatory activities for innate antiviral responses [
 <xref rid="C162" ref-type="bibr">162</xref>].
</p>
